SuRE

Advanced Therapies

Bespoke promoters for safer and more effective cell and gene therapies

Introduction

In advanced therapies, promoter choice is a foundational design decision.

The right regulatory sequence can support cell type-specific, condition-responsive or dose-aware expression. The wrong one can limit safety, efficacy or durability before a therapy reaches its full potential.

SuRE™ is Annogen’s large-scale screening platform for promoter and enhancer development. It combines broad regulatory sequence exploration with sensitive experimental readouts in relevant biological systems, helping teams move from promoter assumptions to validated candidates.

How SuRE™ works

1. Define the required expression behavior
2. Screen a broad regulatory design space
3. Select validated promoter candidates

The SuRE™ platform is a massively parallel reporter assay empirically screening millions of regulatory sequences in vitro and in vivo

SuRE™ example: an exhaustive regulatory profile of the human genome

Annogen’s workflow to engineer and validate bespoke promoter-enhancer hybrids that drive the expression profile needed by your therapy

What makes SuRE™ different

High-throughput screening

Test thousands of promoter and enhancer candidates in one experiment, instead of iterating through a few designs at a time.

Sensitive, reproducible readouts

Measure subtle differences in regulatory activity with the sensitivity needed to separate real signal from screening noise.

Relevant biological systems

Screen in the systems that best reflect how your final constructs will be used, including primary cells, lentiviral configurations and AAV or episomal contexts.

Applications

Tailored promoter development

Develop proprietary promoters around your therapeutic gene, target cell and required expression behavior. 

Off-the-shelf promoters

Start from validated regulatory sequences when your therapy needs a faster route to expression control. 

Base editing

Identify regulatory DNA positions that can modulate endogenous gene expression toward therapeutic effect. 

In vivo screening

Move promoter screening closer to therapeutic reality. 

SuRE™ can be used in lentiviral and AAV-based configurations, enabling parallel assessment of regulatory sequences in advanced therapy-relevant models including mouse, pig and NHP. This reveals promoter behavior that may not be visible in standard cell based models, or where in vitro models are not available.

Trusted by

“To me, imagining the possibilities of SuRE™ applications feels like walking in a candy store.”

Dr. Martijn Kelder, Chief Strategy Officer

Related expertise

AIM™

Map genomic integration sites when transgene expression depends on genomic context as well as regulatory sequence design.

What is Annogen's SuRE platform and what does it do?
How many sequences can you test in a single experiment?
Is the readout transcriptional (RNA) or protein-level?
Do you have an alternative to the TET system (to avoid third-party IP)?
Do your promoters lose expression or silence over time?
In which species has the platform been demonstrated?
Can I get exclusive rights, or only a non-exclusive licence?

Frequently Asked Questions

We imagine there could be some question you want to ask us. Discover the most frequently asked questions about this subject right here. 

This website uses cookies

We use cookies to personalize content, provide social media features, and analyze our traffic. We also share information about your use of our site with our analytics partners. You can change your preferences at any time. For more information, please see our Privacy Policy and Cookie Policy.